As part of its commitment to furthering the quality of education in the field of multiple sclerosis (MS), Biogen Idec (NASDAQ: BIIB) is proud to announce that it provided grants to twelve prestigious universities and medical centers across the country for the 2010-2011 academic year. The grants...
Biogen Idec (NASDAQ: BIIB) and Knopp Neurosciences announced they have entered into an exclusive, worldwide license agreement under which Biogen Idec will develop and commercialize KNS-760704 (dexpramipexole) for the treatment of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's...
Roche (SIX: RO, ROG; OTCQX: RHHBY), Genentech, Inc. a wholly owned member of the Roche Group, and Biogen Idec (Nasdaq: BIIB) announced a Phase III study (STAGE) of the investigational humanized anti-CD20 monoclonal antibody ocrelizumab given in combination with methotrexate (MTX) met its primary...
Biogen Idec (NASDAQ: BIIB) today announced that its oral compound BG-12 (dimethyl fumarate) achieved key milestones in clinical trials for multiple sclerosis (MS) and rheumatoid arthritis (RA). In recent months, the last patient was enrolled in the CONFIRM trial, the second of two Phase III...